Peter Kaboli. Show Affiliations »
Abstract
Mesh: See more » Cost-Benefit AnalysisEconomics, PharmaceuticalPharmacists/economicsPharmacists/statistics & numerical dataUnited States
Year: 2008 PMID: 18541681 DOI: 10.2146/ajhp080191
Source DB: PubMed Journal: Am J Health Syst Pharm ISSN: 1079-2082 Impact factor: 2.637